Keywords: isis/lilly, ly2181308, advances, clinic, isis, pharmaceuticals, says

Isis/Lilly's LY2181308 advances to clinic

Article | 22 November 2004

Print This

Isis Pharmaceuticals says that LY2181308, the first antisense drug to emerge from its drug discovery collaboration with Eli Lilly, has ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in